Table 4.

Summary of vascular access event rates from DHD Programs with five or more patients, 1998 to 2004

Center/ReferenceDaily GroupControl GroupRRP
Follow-Upa (Yr)Event Ratea (per Yr)TypeFollow-Upa (Yr)Event Ratea(per Yr)
Access dysfunction
    All accesses combined
        Turin, Italy (25)50.90.28Parallel103.30.340.8NS
        multicenter, United States/Europe (16)c238.60.05Pre–post50.50.280.2<0.001
        Mountain View, CA, USA (14)68.90.94Pre–post37.51.010.9NS
        multicenter, United States (74)34.00.79None
    Arteriovenous fistulae
        London, Canada (7)bNR0.52 ± 1.47ParallelNR0.18 ± 0.522.9NS
        Mountain View, CA, USA (14)15.30.59Pre–post900.272.2NR
        Lyon, France (17)210.01Pre–post210.150.04NS
        multicenter, United States (15)21.10.52None
    Arteriovenous grafts
        London, Canada (7)bNR1.58 ± 1.79ParallelNR2.12 ± 1.950.7NS
        Mountain View, CA, USA (14)44.91.16Pre–post24.71.131.0NR
        multicenter, United States (15)8.751.37None
    Catheters
        London, Canada (7)bNR3.73 ± 4.42ParallelNR4.51 ± 6.960.8NS
        Mountain View, CA, USA (14)8.80.46Pre–post5.21.530.3NR
        multicenter, United States (15)4.21.44None
Permanent access failures
    All accesses combined
        Turin, Italy (25)50.90.16Parallel103.30.141.1NR
        multicenter, United States (15)31.30.12None
    Arteriovenous fistulae
        Perugia, Italy (21)7.60.02Parallel35.10.100.2<0.01
        Catanzaro, Italy (19)106.30.02None
  • RR, relative risk; NR, not reported; NS, not significant.

  • a Follow-up is in total patient years, except for Mountain View (14), and Lyon (17), which reported total access-years. Similarly, event rates are reported as number per patient-year, except for Mountain View (14) and Lyon (17), which reported number per access-year.

  • b London Study data include 12 patients on nocturnal HD.

  • c A total of 31% of the 72 patients in this study survived for ≥1 yr, and 95% had an arteriovenous fistula.